Roila, Fausto

Roila, Fausto  

Mostra records
Risultati 1 - 20 di 135 (tempo di esecuzione: 0.026 secondi).
Titolo Data di pubblicazione Autore(i) File
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients 2016 Roila, F; Molassiotis, A; Herrstedt, J; Aapro, M; Gralla, Rj; Bruera, E; Clark-Snow, Ra; Dupuis, Ll; Einhorn, Lh; Feyer, P; Hesketh, Pj; Jordan, K; Olver, I; Rapoport, Bl; Roscoe, J; Ruhlmann, Ch; Walsh, D; Warr, D; van der Wetering, M
2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy 2017 Herrstedt, J; Roila, F; Warr, D; Celio, L; Navari, Rm; Hesketh, Pj; Chan, A; Aapro, Ms
2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy 2017 Roila, F; Warr, D; Hesketh, Pj; Gralla, R; Herrstedt, J; Jordan, K; Aapro, M; Ballatori, E; Rapoport, B
2016 updated MASCC/ESMO consensus recommendations: prevention of radiotherapy-induced nausea and vomiting 2017 Ruhlmann, Ch; Jahn, F; Jordan, K; Dennis, K; Maranzano, E; Molassiotis, A; Roila, F; Feyer, P
A new payment-by-results method for determining the fair price of new oncological drugs 2015 Ballatori, E; Ferrante, L; Ruggeri, B; Roila, F
A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin 2017 Bossi, P; Cortinovis, D; Fatigoni, S; Rocca, Mc; Fabi, A; Seminara, P; Ripamonti, C; Alfieri, S; Granata, R; Bergamini, C; Agustoni, F; Bidoli, P; Nole, F; Pessi, Ma; Macchi, F; Michellini, L; Montanaro, F; Roila, F
A review of olanzapine as an antiemetic in chemotherapy-induced nausea and vomiting and in palliative care patients 2015 Fonte, C; Fatigoni, S; Roila, F
Acute emesis: moderately emetogenic chemotherapy 2011 Herrstedt, J; Rapoport, B; Warr, D; Roila, F; Bria, E; Rittenberg, C; Hesketh, Pj
Anticipatory Nausea, Risk Factors, and Its Impact on Chemotherapy-Induced Nausea and Vomiting: Results From the Pan European Emesis Registry Study 2016 Molassiotis, A; Lee, Ph; Burke, Ta; Dicato, M; Gascon, P; Roila, F; Aapro, M
Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009 2011 Jordan, K; Roila, F; Molassiotis, A; Maranzano, E; Clark-Snow, Ra; Feyer, P
Aprepitant (AP) versus dexamethasone (D) for preventing delayed emesis induced by anthracyclines plus cyclophosphamide (A plus C) chemotherapy (CT) in breast cancer patients (pts): A double-blind, multicenter, randomized study 2013 Roila, F; Ballatori, E; Fabi, A; Fatigoni, S; Chiara, S; Ionta, Mt; Aieta, M; Clerico, M; Palladino, Ma; Indelli, M; Garrone, O; Bustreo, S; Ruggeri, B
Aprepitant Versus Dexamethasone for Delayed Emesis: What Is the Role of the 5-Hydroxytryptamine Type 3 Receptor Antagonist Palonosetron? Reply 2014 Roila, F; Fatigoni, S; Ballatori, E
Aprepitant Versus Dexamethasone for Preventing Chemotherapy-Induced Delayed Emesis in Patients With Breast Cancer: A Randomized Double-Blind Study 2014 Roila, F; Ruggeri, B; Ballatori, E; Del Favero, A; Tonato, M
Aprepitant versus metoclopramide, both combined with dexamethasone, for preventing cisplatin-induced delayed emesis: A randomized, double-blind study 2014 Roila, F; Ballatori, E; Ruggeri, B; Fatigoni, S; Mirabile, A; Frau, B; Cavanna, L; Fava, S; Colantonio, I; Angelelli, L; Ciuffreda, L; Lutrino, Se; Zerilli, F
Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: A randomized, double-blind study 2015 Roila, F; Ruggeri, B; Ballatori, E; Fatigoni, S; Caserta, C; Licitra, L; Mirabile, A; Ionta, Mt; Massidda, B; Cavanna, L; Palladino, Ma; Tocci, A; Fava, S; Colantonio, I; Angelelli, L; Ciuffreda, L; Fasola, G; Zerilli, F
Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial) 2020 Gelsomino, F.; Lamberti, G.; Tiseo, M.; Rocco, D.; Pasello, G.; Cecere, F. L.; Chella, A.; Grilli, G.; Mandruzzato, M.; Tognetto, M.; Garassino, M. C.; Macerelli, M.; Novello, S.; Roila, F.; Colantonio, I.; Grossi, F.; Fiorentino, M.; Ardizzoni, A.
BRAFV600 variant allele frequency predicts outcome in metastatic melanoma patients treated with BRAF and MEK inhibitors 2023 Mandala', M.; Palmieri, G.; Ludovini, V.; Baglivo, S.; Marasciulo, F.; Castiglione, F.; Gili, A.; Osellaabate, S.; Rubatto, M.; Senetta, R.; Avallone, G.; Ribero, S.; Romano, L.; Pimpinelli, N.; de Giorgi, V.; Roila, F.; Pisano, M.; Casula, M.; Manca, A.; Sini, M. C.; Massi, D.; Quaglino, P.
Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: An effective but still broken option 2019 Ricciuti, B.; Lamberti, G.; Roila, F.; Metro, G.
Cancer-related fatigue: ESMO Clinical Practice Guidelines for diagnosis and treatment 2020 Fabi, A.; Bhargava, R.; Fatigoni, S.; Guglielmo, M.; Horneber, M.; Roila, F.; Weis, J.; Jordan, K.; Ripamonti, C. I.
Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines 2010 Bovelli, D; Plataniotis, G; Roila, F